CN101835498B - 用于制备与亲水的生物学分布配体偶联的偕二膦酸酯稳定层覆盖的纳米颗粒的方法 - Google Patents

用于制备与亲水的生物学分布配体偶联的偕二膦酸酯稳定层覆盖的纳米颗粒的方法 Download PDF

Info

Publication number
CN101835498B
CN101835498B CN200880110117.8A CN200880110117A CN101835498B CN 101835498 B CN101835498 B CN 101835498B CN 200880110117 A CN200880110117 A CN 200880110117A CN 101835498 B CN101835498 B CN 101835498B
Authority
CN
China
Prior art keywords
group
aliphatic
mol
core
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880110117.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN101835498A (zh
Inventor
M·波尔
O·卢梭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guerbet SA
Original Assignee
Guerbet SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet SA filed Critical Guerbet SA
Publication of CN101835498A publication Critical patent/CN101835498A/zh
Application granted granted Critical
Publication of CN101835498B publication Critical patent/CN101835498B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1842—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a phosphate or a phosphonate, not being a phospholipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B11/00—Diaryl- or thriarylmethane dyes
    • C09B11/04—Diaryl- or thriarylmethane dyes derived from triarylmethanes, i.e. central C-atom is substituted by amino, cyano, alkyl
    • C09B11/10—Amino derivatives of triarylmethanes
    • C09B11/24—Phthaleins containing amino groups ; Phthalanes; Fluoranes; Phthalides; Rhodamine dyes; Phthaleins having heterocyclic aryl rings; Lactone or lactame forms of triarylmethane dyes
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/0033—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through a sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0066—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/02—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
    • C09B23/08—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines
    • C09B23/083—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines five >CH- groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN200880110117.8A 2007-10-05 2008-10-06 用于制备与亲水的生物学分布配体偶联的偕二膦酸酯稳定层覆盖的纳米颗粒的方法 Active CN101835498B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0758103A FR2921838A1 (fr) 2007-10-05 2007-10-05 Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
FR0758103 2007-10-05
PCT/FR2008/051802 WO2009053596A2 (fr) 2007-10-05 2008-10-06 Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile

Publications (2)

Publication Number Publication Date
CN101835498A CN101835498A (zh) 2010-09-15
CN101835498B true CN101835498B (zh) 2016-08-24

Family

ID=39242259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880110117.8A Active CN101835498B (zh) 2007-10-05 2008-10-06 用于制备与亲水的生物学分布配体偶联的偕二膦酸酯稳定层覆盖的纳米颗粒的方法

Country Status (10)

Country Link
US (1) US8722018B2 (enExample)
EP (1) EP2205284B1 (enExample)
JP (1) JP5632287B2 (enExample)
KR (1) KR101523404B1 (enExample)
CN (1) CN101835498B (enExample)
BR (1) BRPI0818433A2 (enExample)
DK (1) DK2205284T3 (enExample)
ES (1) ES2400980T3 (enExample)
FR (1) FR2921838A1 (enExample)
WO (1) WO2009053596A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2921837B1 (fr) * 2007-10-05 2015-07-31 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice organique couplee a des ligands de ciblage
AU2010236189B2 (en) * 2009-04-17 2015-01-29 Li-Cor, Inc. Fluorescent imaging with substituted cyanine dyes
US9205155B2 (en) 2009-10-30 2015-12-08 General Electric Company Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
WO2012054784A1 (en) 2010-10-20 2012-04-26 Li-Cor, Inc. Fluorescent imaging with substituted cyanine dyes
EP3494974B1 (en) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
JP6240599B2 (ja) 2011-07-19 2017-11-29 セルモザイク， インコーポレイテッド 新規の架橋試薬、高分子、治療用コンジュゲートおよびその合成法
CN103945869A (zh) * 2011-08-31 2014-07-23 马林克罗特有限公司 使用h-膦酸酯-烯/-炔的氢膦酸酯化反应进行的靶向纳米颗粒的远程组装
EP2572736A1 (en) * 2011-09-23 2013-03-27 Spago Imaging AB Nanostructures comprising manganese
US9474810B2 (en) 2012-03-02 2016-10-25 General Electric Company Superparamagnetic nanoparticles with PEG substituted α-hydroxy phosphonate shells
US20150079007A1 (en) * 2012-04-20 2015-03-19 Board Of Regents Of The University Of Nebraska Tunable multimodal nanoparticles and methods of use thereof
CN103911017B (zh) * 2012-12-28 2017-09-15 浙江海正药业股份有限公司 菁染料化合物及其制备方法、用于光动力学疗法的双重功能剂及其制备方法
JP6590802B2 (ja) 2013-11-06 2019-10-16 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体
WO2017201528A1 (en) 2016-05-20 2017-11-23 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
US11826426B2 (en) 2017-08-02 2023-11-28 The University Of Chicago Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
WO2020247604A1 (en) * 2019-06-04 2020-12-10 Trustees Of Tufts College Synthetic lipids for mrna delivery
WO2022271671A1 (en) * 2021-06-21 2022-12-29 The Regents Of The University Of Colorado, A Body Corporate Indocarbocyanine lipid derivatives for in vivo cargo delivery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1744920A (zh) * 2002-12-20 2006-03-08 古尔比特公司 被偕二膦酸酯衍生物覆盖的新型磁性颗粒组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021240A2 (de) * 1993-03-17 1994-09-29 Silica Gel Ges.M.B.H Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
DE10222481A1 (de) * 2002-05-22 2003-12-04 Eucro Europe Contract Res Gmbh Kontrastmittel für die Verwendung in bildgebenden Verfahren
FR2856689A1 (fr) * 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
ITFI20060006A1 (it) * 2006-01-04 2007-07-05 Colorobbia Italiana Spa Nanoparticelle funzionalizzate, loro produzione ed uso
FR2921837B1 (fr) 2007-10-05 2015-07-31 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice organique couplee a des ligands de ciblage

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1744920A (zh) * 2002-12-20 2006-03-08 古尔比特公司 被偕二膦酸酯衍生物覆盖的新型磁性颗粒组合物

Also Published As

Publication number Publication date
US20100215586A1 (en) 2010-08-26
JP2010540605A (ja) 2010-12-24
ES2400980T3 (es) 2013-04-15
BRPI0818433A2 (pt) 2015-04-22
DK2205284T3 (da) 2013-03-11
WO2009053596A2 (fr) 2009-04-30
US8722018B2 (en) 2014-05-13
FR2921838A1 (fr) 2009-04-10
KR101523404B1 (ko) 2015-05-27
KR20100080784A (ko) 2010-07-12
JP5632287B2 (ja) 2014-11-26
EP2205284A2 (fr) 2010-07-14
CN101835498A (zh) 2010-09-15
EP2205284B1 (fr) 2012-12-05
WO2009053596A3 (fr) 2009-12-23

Similar Documents

Publication Publication Date Title
CN101835498B (zh) 用于制备与亲水的生物学分布配体偶联的偕二膦酸酯稳定层覆盖的纳米颗粒的方法
Zhang et al. Self-assembled coatings on individual monodisperse magnetite nanoparticles for efficient intracellular uptake
Shen et al. Iron oxide nanoparticle based contrast agents for magnetic resonance imaging
Basly et al. Effect of the nanoparticle synthesis method on dendronized iron oxides as MRI contrast agents
Yoon et al. Surface modification of exfoliated layered gadolinium hydroxide for the development of multimodal contrast agents for MRI and fluorescence imaging
Chen et al. Modification of magnetic silica/iron oxide nanocomposites with fluorescent polymethacrylic acid for cancer targeting and drug delivery
KR101999853B1 (ko) 진단 영상화용 나노입자 조영제
US20080213189A1 (en) Multifunctional metal-graphite nanocrystals
US20060018835A1 (en) Nanoparticles with inorganic core and methods of using them
CN105462580B (zh) 一种荧光靶向的锌掺杂四氧化三铁纳米颗粒及制备
CA2672810A1 (en) Magnetic nanoparticles for the application in hyperthermia, preparation thereof and use in constructs having a pharmacological application
Yue et al. Ultrasmall europium, gadolinium, and dysprosium oxide nanoparticles: Polyol synthesis, properties, and biomedical imaging applications
US20160000942A1 (en) Mri contrast agent including t1 contrast material coated on surface of nanoparticle support
Yin et al. Fluorescent oligo (p-phenyleneethynylene) contained amphiphiles-encapsulated magnetic nanoparticles for targeted magnetic resonance and two-photon optical imaging in vitro and in vivo
KR101097907B1 (ko) 표면개질된 층상 가돌리늄 히드록사이드, 그의 제조방법 및 그를 포함하는 ｍｒｉ 조영제
Carron et al. Potential theranostic and multimodal iron oxide nanoparticles decorated with rhenium–bipyridine and–phenanthroline complexes
US8816107B2 (en) Functionalised nanoparticles, their production and use
CN105797175B (zh) PAAs@MnO(OH)-RGD药物释放载体的制备方法及应用
Řehoř et al. 1H NMR relaxivity of aqueous suspensions of titanium dioxide nanoparticles coated with a gadolinium (III) chelate of a DOTA-monoamide with a phenylphosphonate pendant arm
JP4894332B2 (ja) 磁気共鳴画像用造影剤
KR101159068B1 (ko) 분자영상 프로브 제조용 신규 리간드, 그 리간드를 포함하는 분자영상 프로브, 그 분자영상 프로브를 포함하는 분자영상 입자, 그 제조방법 및 그것을 포함하는 약학 조성물
KR101131724B1 (ko) 실리카 나노구, 그의 제조방법 및 그를 포함하는 ｍｒｉ 조영제
CN106620728A (zh) 一种两性离子修饰的多功能Mn3O4纳米颗粒磁共振成像造影剂及其制备和应用
JP6611624B2 (ja) 抗癌剤、抗癌剤の制御方法
CN112057610A (zh) 一种超小纳米免疫增强剂-抗原复合纳米粒子及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant